Therefore, exploring the inhibition of the VEGFR/FLT4 pathway may offer a promising strategy for preventing tumor lymphangiogenesis and metastasis in NSCLC [47,48]. The gene discussed is FLT4; the disease is non-small cell lung carcinoma.